Penile metastasis from colon cancer with BRAFV600E mutation treated with BRAF/MEK-targeted therapy plus cetuximab: A case report

Figure 1 Computed tomography scans of the patient upon admission: The diseased segment exhibited thickening of the intestinal wall, rough surface texture, and significantly increased enhancement on the enhanced scan. The proximal colon was obstructive dilatation.

Figure 2 Changes in tumor markers during treatment. AFP: Alpha fetoprotein; CEA: Carcinoembryonic antigen; CA: Carbohydrate antigen.

Figure 3 Hematoxylin and eosin staining of colonic mass and penile mass. The penis mass microscopic pathology performance similar to the colonic mass, considering penile metastasis from colon cancer. A: Colonic mass (original magnification × 100); B: Colonic mass (original magnification × 200); C: Penile mass (original magnification × 40); D: Penile mass (original magnification × 100); E: Penile mass (original magnification × 200); F: Penile mass (original magnification × 400).

Figure 4 The immunohistochemical staining results of the penile mass indicated a colonic origin. A: CDX2 (original magnification × 100); B: CK20 (original magnification × 100); C: SATB2 (original magnification × 100).

Figure 5 Timeline of the patient's treatment course. SD: Stable disease; FOLFOXIRI: 5-FU, 2800 mg/m², 48-hour continuous intravenous (i.v.) infusion; leucovorin, 200 mg/m²i.v.; irinotecan, 165 mg/m²; oxaliplatin, 85 mg/m²i.v.